Free Trial
NASDAQ:VYNE

VYNE Therapeutics Q1 2024 Earnings Report

VYNE Therapeutics logo
$0.38 +0.01 (+3.32%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$0.37 -0.01 (-1.88%)
As of 07:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VYNE Therapeutics EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.24
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

VYNE Therapeutics Revenue Results

Actual Revenue
$0.10 million
Expected Revenue
$0.10 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

VYNE Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

VYNE Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Friday, August 15, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

VYNE Therapeutics Earnings Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
See More VYNE Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VYNE Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VYNE Therapeutics and other key companies, straight to your email.

About VYNE Therapeutics

VYNE Therapeutics (NASDAQ:VYNE), a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

View VYNE Therapeutics Profile

More Earnings Resources from MarketBeat